New ECLIPSE study validates the accuracy of Shield.  See the data

Patients who are not up to date with screening
are at increased risk of CRC mortality1

Did you know?

Over 75% of people who died from CRC
were not up to date with screening1

CRC remains the second-leading
cause of cancer-related deaths in
Hong Kong.2

CRC screening can drastically increase survival outcomes when detected early3



Early Stage
Late Stage
Sadly, low screening compliance may contribute to over half of patients
getting diagnosed after their disease has spread.4,5

Blood-based CRC screening fits right in.
Simply done.

Rack of test tubes with blood.

ShieldTM is a blood test that can be completed at any patient visit6,7

A blood-based approach is the patient-preferred screening option for CRC8*

Patients icon.

This option fits into patients’ schedules and breaks through screening
barriers since it requires9

No special preparation
No dietary changesNo sedation
No sedationNo dietary changes
No extra time away
from family or work
Doctor icon.

It also fits right into a provider’s practice

If providers can order a complete blood count for their patients, they’re equipped to order
a blood-based CRC screening test.8

Shield demonstrated 90% compliance in real-world clinical settings.10,11†

ECLIPSE validates Shield as a high-sensitivity blood test for CRC screening that is easy to complete

CRC Overall

ECLIPSE is one of the largest studies and the first of its kind to validate a blood test that detects CRC with high sensitivity13

  • Validated Shield in over 10,000 patients10
  • Included a diverse population representative of US demographics with broad ethnic and socioeconomic backgrounds12,13¶
  • Patients aged 45 to 84 at average risk for CRC13§

Results are consistent with a growing body of evidence that demonstrates the high sensitivity of our blood-based technology.14

How Guardant Health’s blood-based approach identifies CRC6,7,15

Our technology achieves high sensitivity by applying a multimodal approach to detect CRC signals in the bloodstream, including DNA that is shed by tumors.6,7,15

*In a study, patients who initially refused colonoscopy preferred screening with a blood-based test over a stool-based test 83% vs 15%, respectively.8

†Compliance rate for the first 8,000 patients that were prescribed Shield and completed it.6

‡The ECLIPSE study (NCT04136002) is comparing the sensitivity and specificity of cfDNA only Shield with findings from subsequent colonoscopy in over 10,000 average-risk patients.10,12

§Patients had no prior diagnosis of CRC, inflammatory bowel disease, or family history of genetic risk for CRC (eg, Lynch syndrome).12

||Specificity detected for advanced neoplasia defined in ECLIPSE as CRC or advanced adenomas.10,13

¶With more than 200 clinical trial sites in rural and urban communities across 34 states, study participant demographics included 13% Black, 15% Hispanic, and 7% Asian American populations. The study achieved above-average enrollment among Black Americans for a clinical trial.12,16

cfDNA=cell-free DNA.

Shield™ is a qualitative laboratory developed test intended to detect colorectal neoplasia by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
  • The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
  • Patients with an "abnormal signal detected" Shield test result should be referred for colonoscopic evaluation
  • A "normal signal detected" Shield test result does not preclude the presence of colorectal neoplasia, and patients should continue participating in guideline-recommended screening programs
  • Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
References 1. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156(1):63-74. doi:10.1053/j.gastro.2018.09.040 2. Hong Kong Cancer Registry, Hospital Authority 10 most common cancers in Hong Kong in 2021. Updated November 2022. Accessed Nov 23, 2023. 3. National Cancer Institute. Cancer Stat Facts: Colorectal Cancer. website. Accessed July 24, 2023. 4. National Cancer Institute. Colon and rectum stage distribution of SEER incidence cases, 2009-2018. Accessed November 10, 2021. 5. Andrew AS, Parker S, Anderson JC, et al. Risk factors for diagnosis of colorectal cancer at a late stage: a population-based study. J Gen Intern Med. 2018;33(12):2100-2105. doi:10.1007/s11606-018-4648-7 6. Chung D, Gray DM, Greenson J, et al. 913e Clinical validation of a cell-free DNA blood-based test for colorectal cancer screening in an average risk population. Gastroenterology. 2023;164(6):S. doi:10.1016/S0016-5085(23)04760-1 7. Westesson O, Axelrod H, Dean J, et al. Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer. Cancer Res. 2020;80(suppl 16):2316. doi:10.1158/1538-7445.AM2020-2316 8. Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14:183. doi:10.1186/1471-230X-14-183 9. Rich T, Raymond V, Lang K. Where are we today? Efforts to understand strategies and barriers to physician issuance of a recommendation for colorectal cancer screening: a systematic review. Gastroenterology. 2020;158(6 suppl 1):S-918. doi:10.1016/S0016-5085(20)32981-4 10. Data on file. Guardant Health, Inc. 11. Guardant Health. Q3 2022 Earnings Call. Accessed November 30, 2022. 12. Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer. December 15, 2022. Accessed December 15, 2022. 13. Evaluation of the ctDNA LUNAR test in an average patient screening episode (ECLIPSE). identifier: NCT04136002. Updated September 22, 2021. Accessed November 24, 2021. 14. D’Auria K, Chang Y, Multhaup M, et al. Validation of a multi-modal blood-based test for the detection of colorectal cancer with sub single molecule sensitivity. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Chicago, IL. 15. Dean J, He Y, Raymond V, et al. Plasma based cell-free circulating tumor DNA (ctDNA) assessment for non-invasive detection of colorectal cancer (CRC). Gastroenterology. 2020;158(6 suppl 1):S-369. doi:10.1016/S0016-5085(20)31616-4 16. US Food and Drug Administration. 2020 Drug Trials Snapshots Summary Report. Accessed November 29, 2022.